Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A de Jonge

Showing results (201-210 of 223) with videos related to

Pageof 23
Sort By:
Targeted Oncology|February 14, 2019
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic MalignanciesMaja J A de Jonge, Neeltje Steeghs, Martijn P Lolkema, et al.
Cancers|March 11, 2023
Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World DataSophie H A E Derks, Joost L M Jongen, Edgar L van der Meer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Neuro-Oncology Advances|March 7, 2025
Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitorsSophie H A E Derks, Li Shen Ho, Stephan R Koene, et al.
Investigational New Drugs|November 1, 2019
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Investigational New Drugs|January 10, 2018
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancerDiane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, et al.
Investigational New Drugs|October 23, 2019
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Obesity Surgery|August 17, 2024
Post-Bariatric Hypoglycemia: an Impaired Metabolic Response to a MealÖmrüm Aydin, Abraham S Meijnikman, Patrick A de Jonge, et al.
The Oncologist|September 5, 2006
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled studyFloris A de Jong, Diederik F S Kehrer, Ron H J Mathijssen, et al.
British Journal of Cancer|April 17, 2014
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumoursN A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, et al.
Pageof 23

Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
Targeted Oncology|February 14, 2019
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic MalignanciesMaja J A de Jonge, Neeltje Steeghs, Martijn P Lolkema, et al.
Cancers|March 11, 2023
Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World DataSophie H A E Derks, Joost L M Jongen, Edgar L van der Meer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.
Neuro-Oncology Advances|March 7, 2025
Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitorsSophie H A E Derks, Li Shen Ho, Stephan R Koene, et al.
Investigational New Drugs|November 1, 2019
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Investigational New Drugs|January 10, 2018
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancerDiane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, et al.
Investigational New Drugs|October 23, 2019
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Obesity Surgery|August 17, 2024
Post-Bariatric Hypoglycemia: an Impaired Metabolic Response to a MealÖmrüm Aydin, Abraham S Meijnikman, Patrick A de Jonge, et al.
The Oncologist|September 5, 2006
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled studyFloris A de Jong, Diederik F S Kehrer, Ron H J Mathijssen, et al.
British Journal of Cancer|April 17, 2014
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumoursN A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, et al.
Pageof 23